Skip to main content Skip to search Skip to main navigation

ICH: Q3D(R2) for elemental impurities reaches Step 2

The draft for the ICH Q3D(R2) Guideline for Elemental Impurities has reached Step 2 on September 25, 2020 and thus the consultation phase. The draft guideline includes, amongst others, corrected PDE values for gold, silver and nickel and a new appendix for impurities that are applied cutaneously or transcutaneously.  

What is regulated by the guideline?  

The ICH Q3D guideline is intended to control elemental impurities and establishes PDE (Permitted Daily Exposure) values for 24 elements. These apply to medicinal products that can be ingested orally, parenterally and via inhalation.  

What is new?  

In revision Q3D(R2), the newly added Appendix 5 also defines limits for impurities in medicinal products that are absorbed cutaneously or transdermally. A basic approach based on a modifying factor (Cutaneous PDE) is presented.  

The PDE values for the following elements in Appendix 2 have been corrected:  

  • Gold (Au): The oral and parenteral PDE was increased from 100 µg/day to 300 µg/day and from 1 µg/day to 3 µg/day for inhalation. 
  • Silver (Ag): The parenteral PDE was increased from 10 to 15 µg/day.  
  • Nickel (Ni): The PDE for inhalation has been increased from 5 µg/day to 6 µg/day.  

This also results in new values for the permitted concentration in µg/g for the respective elements. They are to be used when the content of elemental impurities in medicinal products does not exceed the daily dose of 10 grams per day.  

Furthermore, the monographs for gold and silver in Appendix 3 have been adjusted.  

The draft document is now available for public consultation. The ICH has focused on extracts of the passages that have been revised:

  • Part 1 – Appendix 2 extract : Correction of PDEs for gold, silver and nickel  
  • Part 2 – Appendix 3 extract: Correction of gold monograph  
  • Part 3 – Appendix 3 extract: Correction of silver monograph 
  • Part 4 – new Annex 5 for risk assessment of preparations applied cutaneously and transcutaneuosly 

All proposed changes are marked in red letters.  

The ICH has prepared a summarizing presentation for all changes, which provides a good overview. 


Source: 

ICH: ICH Guideline For Elemental Impurities Q3d(R2) Draft Version 

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

ANVISA: Expands Recognition of Foreign GMP Authorities

ANVISA: Expands Recognition of Foreign GMP Authorities

Brazilian health authority ANVISA has updated the requirements for the recognition of Equivalent Foreign Regulatory Authorities (AREE) and the administrative procedures for Good Manufacturing Practice (GMP) certification (CBPF) through Normative Instruction IN 451/2026. The aim is to streamline and accelerate regulatory processes.
Read more
EDQM: Guidance on Reporting on Disappearances of Medicinal Products

EDQM: Guidance on Reporting on Disappearances of Medicinal Products

The EDQM has published guidance supporting the implementation of Recommendation CM/Rec(2024)3 on reporting medicinal products that disappear from the legal supply chain due to theft, loss or diversion. The initiative follows a European survey that identified shortcomings in reporting and co-ordination of such incidents.

Read more
Damage Control: Complaints and Recalls

Damage Control: Complaints and Recalls

Complaint handling and product recalls are important components of the Pharmaceutical Quality System (PQS). They serve to identify defective medicinal products and ensure that appropriate measures are taken to protect patient safety, as required by law and the competent supervisory authority.

Read more
What are the Phases of a Working Cycle During a Steam Sterilisation Process?

What are the Phases of a Working Cycle During a Steam Sterilisation Process?

Here's the answer:
Read more
EMA: 9 New Nitrosamines for Appendix 1

EMA: 9 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.
Read more
EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

EMA: Reduced Testing of Incoming Starting Materials is a GMP Matter

The European Medicines Agency (EMA) published an update to its “Quality of Medicines: Questions and Answers – Part 2”. The revision concerns the section on “Reduced testing of incoming starting materials”.
Read more
Previous
Next